News (continued)

Gut Microbiota Bioinformatics Services Now Available by the GutFlora Omics Platform of Creative Proteomics GutFlora Omics platform belongs to Creative Proteomics. It has more than 10 years of experience in providing advanced multi-omics services, and provides services and support to customers through comprehensive intestinal flora research solutions. The product manager has recently announced the fully-developed gut microbiota bioinformatics services, which help understand how the gut microbiota colonizes, varies and interacts with the host, and even how to associate with diseases can be of great value in the treatment of these diseases, such as inflammatory bowel disease (IBD), diabetes, mental disorders, and cancers. Intestinal flora, as the general term for the microbial community that resides in the human intestine, is one of the most interesting research focuses in the fields of microbiology, medicine, and genetics in recent years. Research in recent years has gradually revealed the composition and quantity of intestinal flora, how it enters the body, how to assist

Ideal for applications where the smallest volumes of liquid have to be dosed very precisely For the pulsation-free delivery of small volumes of liquids, syringe pumps have been very successful in atomic spectroscopy, the chemical industry or research, as well as in medical technology. In a previous publication, Spetec was able to show that syringe pumps are excellently suited in atomic spectroscopy for the analysis of cell suspensions or nanoparticle suspensions in order to reduce memory effects or blank values. In medical technology, syringe pumps are indispensable for dosing liquid infusions. For long-term applications, there used to be the handicap that the syringes had to be replaced manually for applications that were to run with the same liquid over a long period of time. Thanks to a technical innovation, Spetec GmbH has now succeeded in developing a double syringe pump that no longer has this disadvantage. A simple spindle with offset power transmission to the syringe pushers, driven by a stepper motor, makes it possible to drive two separate syringes

Innovative end-to-end scientific research to be managed in CDD Vault Burlingame, California — December 16, 2020 —Collaborative Drug Discovery (CDD) has today announced that its CDD Vault platform will be implemented by Curve Therapeutics Ltd. (Southampton, UK) to manage its genetically-encoded Microcycle platform and the functional hits and leads generated from it. Curve is an innovative drug discovery company that has developed a screening platform that directly identifies functional modulators of disease targets in their native cellular environment. CDD Vault is a ubiquitous, hosted platform used by research teams at pharma, academia, and biotechs to store, mine and manage chemical, biological, and image data from the discovery process. It allows the secure and seamless sharing of data with external partners in real-time thus facilitating true collaborative discoveries. "It is important that all of our data is easily captured, mined and analyzed and CDD Vault has been straightforward to implement and use. The system will allow us

Jubilant Biosys, a major international contract research organization (CRO), provides comprehensive drug discovery services to the global pharmaceutical industry. The company adopted CDD Vault and digitally transformed its data management, resulting in increased research productivity and customer satisfaction. “Jubilant Biosys’ customers are now able to see their project evolution as it happens, which is a clear advantage for a biotech or pharma when choosing a partner to work in a discovery project” said Remy Hoffmann, Sr Director BD Europe. “The platform facilitates the close interaction between researchers at Jubilant and their project originator counterpart. This real-time conversation makes for true collaborative projects." Read the full case study on Drug Discovery World.

Company forewarns the UK is risking fake COVID-19 vaccines and other medicines without a new system The UK is now facing a significant problem in how it secures the country’s medicines’ supply chain after leaving the EU on January 1st. But rather than view this as an insurmountable problem, FarmaTrust – a UK-based global medical authentication provider – is calling on the UK government to be true to its word and deliver new Brexit benefits. This issue is especially important with the world’s largest ever mass immunisation program currently under way for COVID-19 vaccines – with both AZ and Pfizer vaccines now being rolled out – at the same time as our only means of verifying authenticity is revoked. This issue of drug supply security and authenticity has only been mentioned in passing in Brexit coverage to date, yet many experts warn that the UK’s departure from the EU’s Falsified Medicines Directive (FMD) has created a huge potential risk. FarmaTrust is calling on the Government to seize the initiative and take this as an opportunity to modernise the system and

As a leading manufacturer and supplier of various drug delivery products and services, CD Bioparticles launches a series of block copolymer micelles for global researchers to help solve the challenges faced in the studies such as limited drug-loading efficiency and yield, unpredictable or uncontrollable degradation rate of the drug-loading cargo, or uncontrollable drug delivery profile. These newly released products are applicable for a variety of potential usages, like biocompatible and biodegradable nanomaterials and bulk material fabrications, drug-delivery cargos with controllable delivery profile, and hydrogels with sol-gel transition useful for reversible encapsulation and delivery. Many new products are released in the block copolymer micelles portfolio, such as Triblock Copolymers, which are vinylically reactive for binding into radical chain synthesized polymers, and AB Diblock Copolymers. For the latter products, the Acrylate-polycaprolactone-b-poly(ethylene